CAR-TCR Europe 2021

Memo

With CAR-TCR therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the 'sell-out' therapy that the field had hoped for. The CAR-TCR Summit Europe 2021 will unravel the technical challenges across R and D, translation, scale and delivery to provide your team with the platform to learn, collaborate and gain actionable insights to advance your therapy for clinical and commercial success. This year's focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle, providing more comprehensive analysis across 3 tracks including: Research and Development; Translation; and, Manufacturing and Commercialisation. On Tuesday February 16, 2021 at 9:00 am (ends Thursday February 18, 2021 at 5:00 pm) Prices: Conference Only - Pharma and Biotech Pricing: GBP 1749.00,Conference + 1 Workshop - Pharma and Biotech Pricing: GBP 2048.00,Conference + Workshop Day - Pharma and Biotech Pricing: GBP 2646.00,Conference Only - Academic and Not-for-Profit Pricing: GBP 1399.00,Conference + 1 Workshop - Academic and Not-for-Profit Pricing: GBP 1598.00,Conference + Workshop Day - Academic and Not-for-Profit Pricing: GBP 1996.00,Conference Only - Standard Pricing: GBP 2499.00,Conference + 1 Workshop - Standard Pricing: GBP 2848.00,Conference + Workshop Day - Standard Pricing: GBP 3546.00 URLs: Tickets: https://go.evvnt.com/701670-0?pid=5569 Brochure: https://go.evvnt.com/701670-3?pid=5569 Speakers: Krishnan Viswanadhan, Bristol Myers Squibb, Jian Zhang, GSK, Trevor Bacon, Janssen, Alla Uhrlandt, Janssen, Adrian Bot, Kite, a Gilead Company, Michele Hooper, Kite: A Gilead Company, Valeria Judkowski, Kite, a Gilead Company, Jie Zhang, Novartis, Kelly Page, Takeda Oncology, Leah Sibener, 3T Biosciences, Helen-Tayton Martin, Adaptimmune, Marc van Dijk, Atara Biotherapeutics, Reagan Jarvis, Anocca AB, Blake Aftab, Atara Biotherapeutics, William Shingler, Autolus Ltd., Vasiliki Zochiou, Beacon Targeted Therapies, Eric Alonzo, bluebird bio, Felix Lorenz, Captain T Cell, Steven Kanner, Caribou Biosciences, Hong Ma, CARsgen Therapeutics, David Gilham, Celyad, Yoav Ben-Yaacov, CTG-Pharma, Chris Haqq, Elicio Therapeutics, Alessandra Cesano, ESSA, Michael Koslowski, GammaDelta Therapeutics, Mythili Koneru, Marker Therapeutics, Jan Spanholtz, Glycostem Therapeutics, Volker Huppert, Glycostem Therapeutics, William Cao, Gracell, Ali Mohamad, Immatics, Frank Fan, Legend Biotech, John Maher, Leucid Bio, Rogier Reijmers, Lumicks, Sareina Wu, Genome Frontier Therapeutics, Dolores Schendel, Medigene, Christopher Heery, Precision Biosciences, Francesco Marincola, Refuge Biotechnologies, Wenzhong Guo, Sorrento Therapeutics Inc, Elisa Kieback, T-Knife, Stacey Willard, Isoplexis, Bin Gao, Timmune Biotech, Kimberly Noonan, WindMIL Therapeutics, Laurence Cooper, Ziopharm Oncology, Annie Hubert, Alliance for Regenerative Medicine, Catherine Thieblemont, Hôpital Saint-Louis, Sonia Guedan, IDIBAPS-Hospital Clinic, Maria Castellà, Hopital Clinic-BST, Astero Klampatsa, Institute of Cancer Research, Holger Hoff, Max-Delbrück- Center for Molecular Medicine, Nina Worel, Medical University Vienna, John Johnston, MHRA, Therese Solstad, Norwegian Medicines Agency, Kristine Moltu, Norwegian Medicines Agency, Christian Buchholz, Paul-Ehrlich- Institute, Steven Feldman, Stanford School of Medicine, Qasim Rafiq, University College London, Ramon Klein Geltink, British Columbia Children’s Hospital, James Riley, University of Pennsylvania, Omar Ali, University of Portsmouth